Literature DB >> 12215716

Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception.

Frank Z Stanczyk1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12215716     DOI： 10.1023/a:1020072325818

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  49 in total

Review 1.  Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.

Authors:  R Krattenmacher
Journal:  Contraception       Date:  2000-07       Impact factor: 3.375

2.  Determination of medrogestone in plasma by high-performance liquid chromatography.

Authors:  W J Lin; S J Her; P F Chen; R R Chen
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-09-04

3.  Pharmacokinetic comparison of two triphasic oral contraceptive formulations containing levonorgestrel and ethinylestradiol.

Authors:  F Z Stanczyk; R A Lobo; S T Chiang; T B Woutersz
Journal:  Contraception       Date:  1990-01       Impact factor: 3.375

4.  Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins.

Authors:  A Phillips; K Demarest; D W Hahn; F Wong; J L McGuire
Journal:  Contraception       Date:  1990-04       Impact factor: 3.375

5.  Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.

Authors:  D J Back; S F Grimmer; N Shenoy; M L Orme
Journal:  Contraception       Date:  1987-06       Impact factor: 3.375

Review 6.  Relative potency of progestins used in oral contraceptives.

Authors:  L J Dorflinger
Journal:  Contraception       Date:  1985-06       Impact factor: 3.375

7.  Medroxyprogesterone acetate in human serum.

Authors:  M Mathrubutham; K Fotherby
Journal:  J Steroid Biochem       Date:  1981-08       Impact factor: 4.292

8.  Potency of progestogens in oral contraceptives--further delay of menses data.

Authors:  G I Swyer
Journal:  Contraception       Date:  1982-07       Impact factor: 3.375

9.  Single dose pharmacokinetics of gestodene in women after intravenous and oral administration.

Authors:  U Täuber; J W Tack; H Matthes
Journal:  Contraception       Date:  1989-10       Impact factor: 3.375

10.  Assessment of the potency of orally administered progestins in women.

Authors:  R J King; M I Whitehead
Journal:  Fertil Steril       Date:  1986-12       Impact factor: 7.329
View more
  23 in total

Review 1.  Hormonal Contraceptives and Mood: Review of the Literature and Implications for Future Research.

Authors:  Thalia Robakis; Katherine E Williams; Lexi Nutkiewicz; Natalie L Rasgon
Journal:  Curr Psychiatry Rep       Date:  2019-06-06       Impact factor: 5.285

2.  Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Authors:  Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-03-14       Impact factor: 4.254

3.  Commentary on Tosun et al. (2019): Dynamic changes in sex hormones and smoking cessation.

Authors:  MacKenzie R Peltier; Sherry A McKee
Journal:  Addiction       Date:  2019-07-25       Impact factor: 6.526

Review 4.  New progestogens: a review of their effects in perimenopausal and postmenopausal women.

Authors:  Régine Sitruk-Ware
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.

Authors:  Julia Winkler; Mark Goldammer; Matthias Ludwig; Beate Rohde; Christian Zurth
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-06       Impact factor: 2.441

6.  Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.

Authors:  Elisabeth F Beaber; Diana S M Buist; William E Barlow; Kathleen E Malone; Susan D Reed; Christopher I Li
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

Review 7.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.

Authors:  Celeste Leigh Pearce; Karine Chung; Malcolm C Pike; Anna H Wu
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 8.  Progesterone receptors: form and function in brain.

Authors:  Roberta Diaz Brinton; Richard F Thompson; Michael R Foy; Michel Baudry; Junming Wang; Caleb E Finch; Todd E Morgan; Christian J Pike; Wendy J Mack; Frank Z Stanczyk; Jon Nilsen
Journal:  Front Neuroendocrinol       Date:  2008-02-23       Impact factor: 8.606

9.  Progestin therapy of complex endometrial hyperplasia with and without atypia.

Authors:  Susan D Reed; Linda F Voigt; Katherine M Newton; Rochelle H Garcia; H Kimberly Allison; Meira Epplein; Diana Jordan; Elizabeth Swisher; Noel S Weiss
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.661

10.  Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation.

Authors:  Marie Shamseddin; Fabio De Martino; Céline Constantin; Valentina Scabia; Anne-Sophie Lancelot; Csaba Laszlo; Ayyakkannu Ayyannan; Laura Battista; Wassim Raffoul; Marie-Christine Gailloud-Matthieu; Philipp Bucher; Maryse Fiche; Giovanna Ambrosini; George Sflomos; Cathrin Brisken
Journal:  EMBO Mol Med       Date:  2021-05-27       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.